78.01
-1.57 (-1.97%)
| Previous Close | 79.58 |
| Open | 79.28 |
| Volume | 324,953 |
| Avg. Volume (3M) | 370,426 |
| Market Cap | 1,773,527,552 |
| Price / Earnings (TTM) | 19.95 |
| Price / Earnings (Forward) | 9.29 |
| Price / Sales | 1.91 |
| Price / Book | 3.31 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2026 |
| Profit Margin | -3.12% |
| Operating Margin (TTM) | 7.61% |
| Diluted EPS (TTM) | -1.18 |
| Quarterly Revenue Growth (YOY) | 43.40% |
| Quarterly Earnings Growth (YOY) | -13.90% |
| Total Debt/Equity (MRQ) | 142.03% |
| Current Ratio (MRQ) | 2.66 |
| Operating Cash Flow (TTM) | 80.74 M |
| Levered Free Cash Flow (TTM) | 39.80 M |
| Return on Assets (TTM) | 0.82% |
| Return on Equity (TTM) | -4.57% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Bullish | |
| Stock | ANI Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | -3.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -3.5 |
| Average | 0.10 |
|
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 11.08% |
| % Held by Institutions | 100.39% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Goldentree Asset Management Lp | 31 Mar 2026 | 667,981 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| COOK MEREDITH | - | 80.88 | -500 | -40,440 |
| GUTWERG ORI | - | 79.50 | -2,772 | -220,374 |
| LALWANI NIKHIL | - | 78.71 | -55,000 | -4,329,050 |
| ROWLAND THOMAS ANDREW | - | 79.50 | -459 | -36,491 |
| WALSH PATRICK D | - | 79.80 | -13,973 | -1,121,515 |
| Aggregate Net Quantity | -72,704 | |||
| Aggregate Net Value ($) | -5,747,869 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 79.70 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| COOK MEREDITH | Officer | 13 May 2026 | Automatic sell (-) | 500 | 80.88 | 40,440 |
| WALSH PATRICK D | Director | 13 May 2026 | Sell (-) | 10,000 | 80.88 | 808,800 |
| GUTWERG ORI | Officer | 12 May 2026 | Sell (-) | 2,772 | 79.50 | 220,374 |
| ROWLAND THOMAS ANDREW | Officer | 12 May 2026 | Sell (-) | 459 | 79.50 | 36,491 |
| LALWANI NIKHIL | Officer | 11 May 2026 | Sell (-) | 55,000 | 78.71 | 4,329,050 |
| WALSH PATRICK D | Director | 11 May 2026 | Sell (-) | 3,973 | 78.71 | 312,715 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |